Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II durvalumab + tremelimumab in hormone receptor-positive hypermutated metastatic breast cancer
KCT0003319Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2017
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in breast cancer, sponsored by AstraZeneca. Started Oct 2017; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on KCT0003319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003319.